Payment overview · 2025
General Payments
$2,136.35
93 reported records · 25 companies
Healthcare provider profile · identity verified
Dipesh Deray, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SARASOTA, FL · NPI 1427382407
Verified facts
What the public records show
CMS Open Payments records show Dipesh Deray, MD received $2,136.35 in general payments during 2025 across 93 reported records.
Novo Nordisk Inc accounted for 14.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 34 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Auvelity, Eliquis, Gemtesa, Jardiance, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Farxiga by this doctor in 2024.
Axsome Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Auvelity as an associated drug or biological on 116023 records involving 35298 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Auvelity by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 123 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 123 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 181 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 418 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $312.78 | 14.6% | 11 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $213.06 | 10.0% | 7 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $206.49 | 9.7% | 17 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $184.38 | 8.6% | 8 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $146.01 | 6.8% | 5 | 2025 |
| CVRx, Inc. | Unresolved — no canonical attribution shown | $145.79 | 6.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $121.50 | 5.7% | 7 | 2025 |
| INTUITIVE SURGICAL, INC. | Unresolved — no canonical attribution shown | $105.70 | 5.0% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $101.07 | 4.7% | 5 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $90.23 | 4.2% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $86.28 | 4.0% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $66.48 | 3.1% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $64.96 | 3.0% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $50.96 | 2.4% | 3 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $48.25 | 2.3% | 2 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $38.30 | 1.8% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $23.16 | 1.1% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.68 | 1.0% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $18.25 | 0.8% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.27 | 0.8% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $15.85 | 0.7% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $15.70 | 0.7% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.01 | 0.7% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $14.45 | 0.7% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $13.74 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,118.97 | 92 |
| Education | $17.38 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $297.01 | 10 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $195.68 | 6 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $184.38 | 8 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $167.09 | 15 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $167.09 | 15 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $147.56 | 7 | 2025 |
Source payment records
|
|||||
| Barostim Neo System Normalized: barostim neo system |
Device | CVRx, Inc. | $145.79 | 1 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $118.01 | 4 | 2025 |
Source payment records
|
|||||
| Da Vinci Surgical System Normalized: da vinci surgical system |
Device | INTUITIVE SURGICAL, INC. | $105.70 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $101.07 | 5 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $90.23 | 5 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $88.39 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $87.26 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $87.26 | 5 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $86.28 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $66.48 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $57.62 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $51.37 | 3 | 2025 |
Source payment records
|
|||||
| EVKEEZA Normalized: evkeeza |
Biological | Regeneron Healthcare Solutions, Inc. | $48.25 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $44.26 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $39.40 | 2 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $38.30 | 2 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $38.30 | 2 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $38.30 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $34.24 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $23.16 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $20.68 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $18.25 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $17.27 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $15.85 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $15.70 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $14.45 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $13.74 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $13.59 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Auvelity auvelity |
2025 | Auvelity | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 418 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 123 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 181 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
44 | 14 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
60 | 19 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
45 | 16 |
| Axsome Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | Auvelity open payments reported associated product |
CMS Open Payments — General Payments 116023 supporting records · 35298 recipient NPIs · example record 1235293064 |
Auvelity · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
123 | 42 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
123 | 42 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
104 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
181 | 42 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
418 | 74 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
33 | 31 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1261 | 308 |
| Levothyroxine Sodium | Levothyroxine Sodium | 935 | 205 |
| Amlodipine Besylate | Amlodipine Besylate | 922 | 237 |
| Losartan Potassium | Losartan Potassium | 627 | 174 |
| Lisinopril | Lisinopril | 567 | 154 |
| Trazodone Hcl | Trazodone Hcl | 565 | 105 |
| Gabapentin | Gabapentin | 513 | 101 |
| Metoprolol Tartrate | Metoprolol Tartrate | 453 | 89 |
| Furosemide | Furosemide | 450 | 112 |
| Pantoprazole Sodium | Pantoprazole Sodium | 425 | 132 |
| Eliquis | Apixaban | 418 | 74 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 392 | 124 |
| Metoprolol Succinate | Metoprolol Succinate | 377 | 106 |
| Famotidine | Famotidine | 366 | 56 |
| Potassium Chloride | Potassium Chloride | 342 | 80 |
| Omeprazole | Omeprazole | 324 | 101 |
| Sertraline Hcl | Sertraline Hcl | 272 | 53 |
| Tramadol Hcl | Tramadol Hcl | 269 | 61 |
| Tamsulosin Hcl | Tamsulosin Hcl | 265 | 87 |
| Metformin Hcl | Metformin Hcl | 248 | 81 |
| Mirtazapine | Mirtazapine | 246 | 38 |
| Clopidogrel | Clopidogrel Bisulfate | 219 | 62 |
| Simvastatin | Simvastatin | 213 | 68 |
| Duloxetine Hcl | Duloxetine Hcl | 197 | 38 |
| Divalproex Sodium | Divalproex Sodium | 196 | 24 |
| Alprazolam | Alprazolam | 182 | 56 |
| Ozempic | Semaglutide | 181 | 42 |
| Escitalopram Oxalate | Escitalopram Oxalate | 173 | 60 |
| Allopurinol | Allopurinol | 169 | 40 |
| Azithromycin | Azithromycin | 155 | 111 |
| Atenolol | Atenolol | 154 | 39 |
| Valsartan | Valsartan | 154 | 55 |
| Carvedilol | Carvedilol | 141 | 42 |
| Xarelto | Rivaroxaban | 141 | 28 |
| Citalopram Hbr | Citalopram Hydrobromide | 140 | 34 |
| Meloxicam | Meloxicam | 129 | 41 |
| Fluticasone Propionate | Fluticasone Propionate | 125 | 61 |
| Hydrochlorothiazide | Hydrochlorothiazide | 125 | 39 |
| Jardiance | Empagliflozin | 123 | 42 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 114 | 42 |
| Pravastatin Sodium | Pravastatin Sodium | 113 | 40 |
| Montelukast Sodium | Montelukast Sodium | 111 | 34 |
| Warfarin Sodium | Warfarin Sodium | 109 | suppressed |
| Cephalexin | Cephalexin | 106 | 66 |
| Mounjaro | Tirzepatide | 104 | 18 |
| Memantine Hcl | Memantine Hcl | 100 | 16 |
| Lorazepam | Lorazepam | 99 | 25 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 97 | 19 |
| Donepezil Hcl | Donepezil Hcl | 96 | 25 |
| Spironolactone | Spironolactone | 95 | 22 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 94 | 13 |
| Finasteride | Finasteride | 93 | 28 |
| Tizanidine Hcl | Tizanidine Hcl | 93 | 29 |
| Prednisone | Prednisone | 92 | 29 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 89 | 20 |
| Ezetimibe | Ezetimibe | 88 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 85 | 33 |
| Alendronate Sodium | Alendronate Sodium | 80 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 80 | 17 |
| Verapamil Er | Verapamil Hcl | 80 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 79 | 19 |
| Paroxetine Hcl | Paroxetine Hcl | 78 | 15 |
| Bupropion Xl | Bupropion Hcl | 73 | 22 |
| Methylprednisolone | Methylprednisolone | 72 | 66 |
| Ropinirole Hcl | Ropinirole Hcl | 66 | 19 |
| Glimepiride | Glimepiride | 65 | 15 |
| Breo Ellipta | Fluticasone/Vilanterol | 64 | 17 |
| Buspirone Hcl | Buspirone Hcl | 63 | 23 |
| Celecoxib | Celecoxib | 61 | 18 |
| Myrbetriq | Mirabegron | 60 | 19 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 60 | 16 |
| Propranolol Hcl | Propranolol Hcl | 59 | 15 |
| Topiramate | Topiramate | 59 | suppressed |
| Glipizide | Glipizide | 57 | 12 |
| Ondansetron Odt | Ondansetron | 57 | 30 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 57 | 14 |
| Clonazepam | Clonazepam | 56 | 19 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 56 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 56 | 19 |
| Clonidine Hcl | Clonidine Hcl | 55 | 26 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 55 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 53 | 23 |
| Ibuprofen | Ibuprofen | 53 | 18 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 52 | suppressed |
| Nifedipine Er | Nifedipine | 52 | 11 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 52 | 12 |
| Nebivolol Hcl | Nebivolol Hcl | 51 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 50 | 39 |
| Levetiracetam | Levetiracetam | 49 | suppressed |
| Diazepam | Diazepam | 45 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 45 | 16 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 45 | 22 |
| Latanoprost | Latanoprost | 45 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 45 | 11 |
| Bumetanide | Bumetanide | 44 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 44 | suppressed |
| Synthroid | Levothyroxine Sodium | 44 | 14 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 43 | suppressed |
| Nystatin | Nystatin | 43 | 19 |
| Albuterol Sulfate | Albuterol Sulfate | 42 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 42 | suppressed |
| Entresto | Sacubitril/Valsartan | 41 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 41 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 41 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 40 | suppressed |
| Levemir | Insulin Detemir | 40 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 40 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 39 | 28 |
| Glucagon Emergency Kit | Glucagon | 39 | 18 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 38 | suppressed |
| Eszopiclone | Eszopiclone | 37 | suppressed |
| Lactulose | Lactulose | 36 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 36 | suppressed |
| Januvia | Sitagliptin Phosphate | 35 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 35 | 21 |
| Gemfibrozil | Gemfibrozil | 34 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 33 | suppressed |
| Fenofibrate | Fenofibrate | 33 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 33 | 31 |
| Sevelamer Carbonate | Sevelamer Carbonate | 32 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 31 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 31 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | 17 |
| Trintellix | Vortioxetine Hydrobromide | 31 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 30 | 16 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 30 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 29 | 22 |
| Metformin Hcl Er | Metformin Hcl | 29 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 29 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 29 | suppressed |
| Baclofen | Baclofen | 28 | suppressed |
| Lovastatin | Lovastatin | 28 | suppressed |
| Trimethoprim | Trimethoprim | 28 | suppressed |
| Trulicity | Dulaglutide | 28 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 27 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 27 | suppressed |
| Risperidone | Risperidone | 27 | suppressed |
| Gemtesa | Vibegron | 26 | suppressed |
| Ketoconazole | Ketoconazole | 26 | 12 |
| Torsemide | Torsemide | 26 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Linzess | Linaclotide | 25 | suppressed |
| Pregabalin | Pregabalin | 25 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 24 | suppressed |
| Clonidine | Clonidine | 24 | suppressed |
| Hydrocortisone | Hydrocortisone | 24 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 13 |
| Novolin R | Insulin Regular, Human | 24 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 24 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Chlorthalidone | Chlorthalidone | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Folic Acid | Folic Acid | 23 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 23 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 22 | suppressed |
| Temazepam | Temazepam | 22 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 21 | suppressed |
| Methocarbamol | Methocarbamol | 21 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 21 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 20 | suppressed |
| Mupirocin | Mupirocin | 20 | 15 |
| Oxycodone Hcl | Oxycodone Hcl | 20 | 12 |
| Repatha Sureclick | Evolocumab | 19 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Letrozole | Letrozole | 18 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 18 | 12 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 17 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 17 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 16 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | 14 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 16 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 15 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 15 | suppressed |
| Methotrexate | Methotrexate Sodium | 15 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 15 | suppressed |
| Timolol Maleate | Timolol Maleate | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | 12 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Auvelity | Dextromethorphan Hbr/Bupropion | 13 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 13 | suppressed |
| Calcium Acetate | Calcium Acetate | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 13 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 13 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Humulin R | Insulin Regular, Human | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Budesonide | Budesonide | 11 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 11 | suppressed |
| Insulin Lispro | Insulin Lispro | 11 | suppressed |
| Modafinil | Modafinil | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Rivastigmine | Rivastigmine | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,136.35 · 93 records | Novo Nordisk Inc | AIRSUPRA, Arikayce, Auvelity, BREZTRI, Barostim Neo System, Brinsupri, CAPLYTA, Cologuard Collection Kit, Da Vinci Surgical System, Dexcom G6 Transmitter, ELIQUIS, EVENITY, EVKEEZA, FREESTYLE LIBRE 3, Flector, GEMTESA, GVOKE HYPOPEN, JARDIANCE, Kerendia, LEQVIO, Licart, NURTEC ODT, OTEZLA, Ozempic, REPATHA, REXULTI, Rybelsus, The Cologuard Plus Collection Kit, Tirosint, VOQUEZNA, VRAYLAR, Veozah, ZAVZPRET, ZORYVE | 16 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Auvelity play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error